

September 14, 2023

**To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001**

**To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051**

**Ref: Scrip Code: 532296**

**Ref: Scrip Name: GLENMARK**

Dear Sirs,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you that on the recommendation of Nomination & Remuneration Committee (NRC), the Board has approved promotion of senior managerial persons (SMP), the details of the aforesaid change as prescribed under SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure A.

You are requested to take the same on record.

Thanking You.

Yours faithfully,

**For Glenmark Pharmaceuticals Limited**

**Harish Kuber  
Company Secretary & Compliance Officer**

Encl: As above

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

**Annexure I**

**Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023**

Sr. No.	Particulars	Details	
1.	Name	<b>Mr. Brijlal Motwani</b>	<b>Mr. Indrajit Bose</b>
2.	Reason for change	Promotion from Executive Vice President & Global Head - Formulations Operations to President & Global Head - Formulations Operations	Promotion from Executive Vice President & Chief Quality Officer to President & Chief Quality Officer
3.	Date of promotion & term of appointment	With effect from September 15, 2023 Terms of appointment: Existing Full Time Employment	With effect from September 15, 2023 Terms of appointment: Existing Full Time Employment
4.	Brief Profile	<p>Mr. Brijlal Motwani currently leads operations of ten manufacturing facilities spread across multiple geographies. He also oversees entire demand &amp; supply planning, purchase, project management, and strategic change management initiatives.</p> <p>Before moving into the current role, he was the Head of manufacturing reporting to the Global Head of Formulation Operations. In this role, he was responsible for manufacturing operations, Engineering &amp; Maintenance, EHS, and compliance.</p> <p>He has a Master's in Pharmacy and has three decades of experience in the pharmaceutical industry.</p>	<p>Mr. Indrajit Bose is currently responsible for the entire quality function of the Company. Indrajit has ten sites under his portfolio.</p> <p>Indrajit joined Glenmark in 2022 as Sr. Vice. President &amp; Cluster Head-Quality reporting to the Global Head of Quality &amp; Chief Quality Officer. Indrajit has since assumed the role of Chief Quality Officer.</p> <p>Indrajit has a bachelor's degree in Pharmacy and a total of 32 years of experience in the pharmaceutical industry.</p>
5.	Disclosure of relationships between directors (in case of appointment of a director)	None	None

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com